Biotech entity
All 1 tracked stories fall under one category: pharma. Accu-Fab is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Thomas P. Gallagher, all published on August 8, 2026.
Last mentioned: Aug 8, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
All 1 tracked stories fall under one category: pharma. Accu-Fab is the most frequent co-covered peer, appearing in 1 of the 1 tracked story. Each carries 3 original sources on average. We currently track 1 Biotech story that mention Thomas P. Gallagher, all published on August 8, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 3 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Thomas P. Gallagher. Shared-story counts are live from our verified record — not editorial picks.
Urogen Pharma’s bladder cancer therapy ZUSDURI generated $50.4M in Q2 net product revenue, a 73% sequential jump, as the company activated 1,444 accounts and doubled repeat prescribers. The strong commercial launch highlights robust demand in biotech’s niche oncology space.
Source: themarketsdaily.com · dailypolitical.com
Thomas P. Gallagher is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
